Xencor vs Zymeworks
XNCR and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XNCR and ZYME compare
Xencor is the larger company, worth 1.4 times as much as Zymeworks ($3.0B against $2.1B).
Zymeworks grew revenue faster over the last twelve months (97.8% versus 33.5% for Xencor).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −58.8% at Xencor.
Zymeworks scores higher on the StockData Score (10 against 7 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XNCR | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $2.1B |
| Share price | $39.97 | $29.07 |
| Change, 1 year | 191% | 61.1% |
| Change, 5 years | 8.4% | 46.7% |
| Beta (5Y) | 1.04 | 0.84 |
| Employees | 260 | 264 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 55.9× |
| P/S | 14.8× | 7.8× (better) |
| P/B | 5.3× (better) | 8.0× |
| EV/EBITDA | – | 44.4× |
| FCF yield | −5.9% | −5.5% (better) |
| Fair value | $16.78 | $12.06 |
| Margin of safety | −138% (better) | −141% |
| Growth | ||
| Revenue growth (TTM) | 33.5% | 97.8% (better) |
| Revenue growth, 5Y average | 0.47% | 22.2% (better) |
| Profitability | ||
| Operating margin | −72.7% | 16.6% (better) |
| Net margin | −58.8% | 16.3% (better) |
| FCF margin | −88.0% | −42.4% (better) |
| Return on equity | −19.9% | 15.0% (better) |
| Return on invested capital | −17.4% | 21.4% (better) |
| Financial health | ||
| Debt / equity | 0.17 (better) | 0.00 |
| Interest coverage | −6.2× | – |
| Current ratio | 6.54 (better) | 3.30 |
| Altman Z-score | 7.13 (better) | 0.87 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 113% | 98.1% |
| Held by insiders | 1.6% | 58.9% |
| Insider net buying, 12 months | −$3.9M (better) | −$5.0M |
| Short interest, % of float | 17.6% | 20.3% |
Go deeper
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.